Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Innocan Pharma Corp (CSE: INNO ) 0.2500 +0.0100 (+4.17%) Official Closing Price Updated: 3:56 PM EDT, Jul 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Innocan Pharma Corp CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark May 28, 2024 Innocan Pharma's Q1 2024 revenue surged 334% to $6.8M, driven by strong sales growth from BI Sky Global. Read about financial performance. Via Benzinga This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain April 23, 2024 Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration... Via Benzinga Exposures Product Safety 534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations April 02, 2024 Innocan Pharma's 2023 earnings report: Revenue soars 534%, operating loss down 61%, $1.5M capital raise. CEO shares strategic vision. Via Benzinga CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval February 13, 2024 Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are... Via Benzinga Exposures Product Safety Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024 December 22, 2023 This month, the Indigenous Cannabis Industry Association held its first Indigenous Cannabis Regulators roundtable, bringing together Indigenous Cannabis Regulators from Tribal Nations and... Via Benzinga Topics Cannabis Exposures Cannabis More Cannabis Funding For FDA And Product Expansion: How This Pharma Tech Company Is Doing It October 23, 2023 Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has closed the second and final tranche of its previously announced private placement offering of its units. Via Benzinga Topics Cannabis Exposures Cannabis Product Safety CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare September 21, 2023 Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has entered into an agreement with Research Capital Corporation as the sole agent and sole book-runner on a "best efforts" agency basis... Via Benzinga Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales August 28, 2023 Innocan Pharma Corporation (CSE: INNO)(FSE: IP4) (OTC: INNPF), a pharmaceutical technology firm specializing in innovative drug delivery platforms, Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.